Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
Wednesday, June 5, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Precision BioSciences presented new preclinical safety data for PBGENE-HBV at the European Association for the Study of the Liver Congress. The data indicates that PBGENE-HBV effectively cuts HBV DNA without affecting the human genome. It was well tolerated in multiple administrations, showing no off-target editing, which supports its advancement to clinical trials as a potential curative treatment.
Price reaction · baseline $13.23 (2024-06-04 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
-1.7%
Market Sentiment Analysis
POSITIVE FACTORS
PBGENE-HBV specifically targets HBV DNA.
Well tolerated across multiple administrations.
No off-target editing observed.
Supports advancement to clinical trials.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– PBGENE-HBV specifically cuts HBV DNA without impacting the human genome – PBGENE-HBV was well tolerated across multiple administrations with no off-target editing observed – Preclinical safety data supports advancement of PBGENE-HBV to clinical trials as a potentially curative, finite treatment
Frequently Asked Questions
What is PBGENE-HBV?
PBGENE-HBV is a clinical candidate designed to specifically cut HBV DNA.
How was PBGENE-HBV tolerated?
PBGENE-HBV was well tolerated across multiple administrations.
Were there any off-target effects observed?
No off-target editing was observed during the studies.
What does the safety data support?
The safety data supports advancing PBGENE-HBV to clinical trials.